Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Epilepsia ; 62(7): 1677-1688, 2021 07.
Article in English | MEDLINE | ID: mdl-34080183

ABSTRACT

OBJECTIVE: The kainic acid (KA)-induced status epilepticus (SE) model in rats is a well-defined model of epileptogenesis. This model closely recapitulates many of the clinical and pathological characteristics of human temporal lobe epilepsy (TLE) that arise following SE or another neurological insult. Spontaneous recurrent seizures (SRS) in TLE can present after a latent period following a neurological insult (traumatic brain injury, SE event, viral infection, etc.). Moreover, this model is suitable for preclinical studies to evaluate the long-term process of epileptogenesis and screen putative disease-modifying/antiepileptogenic agents. The burden of human TLE is highly variable, similar to the post-KA SE rat model. In this regard, this model may have broad translational relevance. This report thus details the pharmacological characterization and methodological refinement of a moderate-throughput drug screening program using the post-KA-induced SE model of epileptogenesis in male Sprague Dawley rats to identify potential agents that may prevent or modify the burden of SRS. Specifically, we sought to demonstrate whether our protocol could prevent the development of SRS or lead to a reduced frequency/severity of SRS. METHODS: Rats were administered either everolimus (2-3 mg/kg po) beginning 1, 2, or 24 h after SE onset, or phenobarbital (60 mg/kg ip) beginning 1 h after SE onset. All treatments were administered once/day for 5-7 days. Rats in all studies (n = 12/treatment dose/study) were then monitored intermittently by video-electroencephalography (2 weeks on, 2 weeks off, 2 weeks on epochs) to determine latency to onset of SRS and disease burden. RESULTS: Although no adverse side effects were observed in our studies, no treatment significantly modified disease or prevented the presentation of SRS by 6 weeks after SE onset. SIGNIFICANCE: Neither phenobarbital nor everolimus administered at several time points after SE onset prevented the development of SRS. Nonetheless, we demonstrate a practical and moderate-throughput screen for potential antiepileptogenic agents in a rat model of TLE.


Subject(s)
Anticonvulsants/therapeutic use , Epilepsy, Temporal Lobe/prevention & control , Everolimus/therapeutic use , Phenobarbital/therapeutic use , Animals , Anticonvulsants/adverse effects , Body Weight , Convulsants , Cost of Illness , Disease Models, Animal , Drug Compounding , Drug Discovery , Drug Evaluation, Preclinical , Electroencephalography , Epilepsy, Temporal Lobe/chemically induced , Everolimus/adverse effects , High-Throughput Screening Assays , Kainic Acid , Male , Phenobarbital/adverse effects , Rats , Rats, Sprague-Dawley , Seizures/prevention & control , Translational Research, Biomedical
2.
Pharm Biol ; 56(1): 217-224, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29560767

ABSTRACT

CONTEXT: Temporal lobe epilepsy (TLE) is resistant to antiepileptic drugs (AEDs) and is associated with cognitive impairment. The modern Chinese medicine, compound Danshen dripping pills (CDDP), is clinically effective in treating epilepsy and improving cognitive impairment. OBJECTIVE: This study evaluated the protective effects of CDDP alone and in combination with carbamazepine (CBZ) on kainic acid-induced TLE and cognitive impairment in rats. MATERIALS AND METHODS: Sprague-Dawley rats were randomly divided into five groups: control (sham operated), model, CDDP, CBZ and combined. A TLE model was then created via bilateral intrahippocampal injection of 0.35 µg kainic acid (KA). Rats received CDDP (85 mg/kg), CBZ (100 mg/kg) or combined (85 mg/kg CDDP +100 mg/kg CBZ) via intragastric administration for 90 d, respectively. Seizure intensity, apoptosis and glial cell line-derived neurotrophic factor (GDNF) were measured. Furthermore, the improvement in cognitive impairment and hippocampal neuronal damage was evaluated. RESULTS: CDDP combined with CBZ significantly decreased seizure severity and frequency (p < 0.05) and ameliorated cognitive impairment (p < 0.05). The model group showed a significant reduction of neurons and Bcl-2/Bax expression in the hippocampus CA3 area (p < 0.01), the combined groups significantly reversed these change (p < 0.01). GDNF expression in the combined groups showed a clear increase over the model group (p < 0.05). CONCLUSION: These findings support the use of CDDP as an adjuvant drug for the treatment of TLE and cognitive deficit. Its mechanism might be related to an anti-apoptosis effect and up-regulation of GDNF.


Subject(s)
Anticonvulsants/pharmacology , Behavior, Animal/drug effects , CA3 Region, Hippocampal/drug effects , Carbamazepine/pharmacology , Cognition/drug effects , Cognitive Dysfunction/prevention & control , Drugs, Chinese Herbal/pharmacology , Epilepsy, Temporal Lobe/prevention & control , Kainic Acid , Animals , Apoptosis/drug effects , CA3 Region, Hippocampal/metabolism , CA3 Region, Hippocampal/pathology , CA3 Region, Hippocampal/physiopathology , Camphanes , Cognitive Dysfunction/chemically induced , Cognitive Dysfunction/physiopathology , Cognitive Dysfunction/psychology , Disease Models, Animal , Drug Therapy, Combination , Epilepsy, Temporal Lobe/metabolism , Epilepsy, Temporal Lobe/pathology , Epilepsy, Temporal Lobe/physiopathology , Escape Reaction/drug effects , Glial Cell Line-Derived Neurotrophic Factor/metabolism , Male , Maze Learning/drug effects , Panax notoginseng , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats, Sprague-Dawley , Reaction Time/drug effects , Salvia miltiorrhiza , Time Factors , bcl-2-Associated X Protein/metabolism
3.
Pharm Biol ; 51(12): 1572-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24004105

ABSTRACT

CONTEXT: Temporal lobe epilepsy (TLE) is an intractable neurological disorder. Curcumin is the bioactive component of turmeric with anti-epileptic and neuroprotective potential. OBJECTIVE: The beneficial effect of curcumin on the intrahippocampal kainate-induced model of TLE was investigated. MATERIALS AND METHODS: Rats were divided into sham, curcumin-pretreated sham, kainate and curcumin-pretreated kainate groups. The rat model of TLE was induced by unilateral intrahippocampal injection of 4 µg of kainate. Rats received curcumin p.o. at a dose of 100 mg/kg/d starting 1 week before the surgery. Seizure activity (SE) and oxidative stress-related markers were measured. Furthermore, the Timm index for evaluation of mossy fiber sprouting (MFS) and number of Nissl-stained neurons were quantified. RESULTS: All rats in the kainate group had SE, while 28.5% of rats showed seizures in the curcumin-pretreated kainate group. Malondialdehyde and nitrite and nitrate levels significantly increased in the kainate group (p < 0.01 and p < 0.05, respectively), and curcumin significantly lowered these parameters (p < 0.05). Superoxide dismutase activity significantly decreased in the kainate group (p < 0.05) and curcumin did not improve it. Rats in the kainate group showed a significant reduction of neurons in Cornu Ammonis 1 (CA1) (p < 0.05), CA3 (p < 0.005) and hilar (p < 0.01) regions, and curcumin significantly prevented these changes (p < 0.05-0.005). The Timm index significantly increased in the kainate group (p < 0.005), and curcumin significantly lowered this index (p < 0.01). DISCUSSION AND CONCLUSION: Curcumin pretreatment can attenuate seizures, lower some oxidative stress markers, and prevent hippocampal neuronal loss and MFS in the kainate-induced model of TLE.


Subject(s)
Anticonvulsants/therapeutic use , Curcumin/therapeutic use , Epilepsy, Temporal Lobe/prevention & control , Kainic Acid/pharmacology , Neuroprotective Agents/therapeutic use , Animals , Anticonvulsants/administration & dosage , Behavior, Animal/drug effects , Biomarkers/metabolism , Curcumin/administration & dosage , Disease Models, Animal , Epilepsy, Temporal Lobe/chemically induced , Hippocampus/drug effects , Hippocampus/metabolism , Hippocampus/pathology , Male , Neuroprotective Agents/administration & dosage , Nitrites/metabolism , Oxidative Stress/drug effects , Rats , Rats, Wistar
4.
Nat Med ; 18(8): 1271-8, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22797810

ABSTRACT

Temporal lobe epilepsy (TLE) is accompanied by an abnormal location of granule cells in the dentate gyrus. Using a rat model of complex febrile seizures, which are thought to be a precipitating insult of TLE later in life, we report that aberrant migration of neonatal-generated granule cells results in granule cell ectopia that persists into adulthood. Febrile seizures induced an upregulation of GABA(A) receptors (GABA(A)-Rs) in neonatally generated granule cells, and hyperactivation of excitatory GABA(A)-Rs caused a reversal in the direction of granule cell migration. This abnormal migration was prevented by RNAi-mediated knockdown of the Na(+)K(+)2Cl(-) co-transporter (NKCC1), which regulates the excitatory action of GABA. NKCC1 inhibition with bumetanide after febrile seizures rescued the granule cell ectopia, susceptibility to limbic seizures and development of epilepsy. Thus, this work identifies a previously unknown pathogenic role of excitatory GABA(A)-R signaling and highlights NKCC1 as a potential therapeutic target for preventing granule cell ectopia and the development of epilepsy after febrile seizures.


Subject(s)
Epilepsy, Temporal Lobe/etiology , Nerve Tissue Proteins/physiology , Neurons/pathology , Receptors, GABA-A/physiology , Seizures, Febrile/physiopathology , gamma-Aminobutyric Acid/physiology , Animals , Animals, Suckling , Brain Diseases/etiology , Brain Diseases/physiopathology , Brain Diseases/prevention & control , Bumetanide/pharmacology , Bumetanide/therapeutic use , Cell Lineage , Cell Movement , Choristoma/etiology , Choristoma/physiopathology , Choristoma/prevention & control , Dentate Gyrus , Disease Susceptibility , Epilepsy, Temporal Lobe/physiopathology , Epilepsy, Temporal Lobe/prevention & control , GABA Agonists/therapeutic use , GABA Antagonists/toxicity , Genes, Reporter , Hippocampus/pathology , Hippocampus/physiopathology , Hyperthermia, Induced/adverse effects , Male , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/biosynthesis , Nerve Tissue Proteins/genetics , Neurons/metabolism , Organ Specificity , RNA Interference , Rats , Rats, Sprague-Dawley , Receptors, GABA-A/biosynthesis , Receptors, GABA-A/genetics , Seizures, Febrile/complications , Seizures, Febrile/pathology , Sodium-Potassium-Chloride Symporters/genetics , Sodium-Potassium-Chloride Symporters/physiology , Solute Carrier Family 12, Member 2 , Up-Regulation
5.
J Neurol Sci ; 308(1-2): 21-4, 2011 Sep 15.
Article in English | MEDLINE | ID: mdl-21762929

ABSTRACT

Epileptic seizures may be triggered by both nonspecific facilitating factors and specific reflex epileptic mechanisms. These consist of sensory or cognitive inputs activating neural networks that, due to some functional instability, may respond with an epileptic discharge. The aim of this study was to determine the prevalence and nature of self-perceived seizure-inducing and -inhibiting factors in patients with mesial temporal lobe epilepsy (MTLE) followed from March 3rd to December 8th, 2009 at the Centro de Epilepsia de Santa Catarina Outpatient Clinic of the Hospital Governador Celso Ramos in Florianópolis, Brazil and their relation to demographics, epilepsy-related variables and anxiety level. Of the 71 patients, 60 (84.5%) patients identified at least one seizure trigger, and 36 (50.7%) patients identified inhibiting factors. In order of frequency, the most freely recalled precipitants were nervousness (58.8%), worrying (21.6%) and menstruation (19.6%), while the precipitants that were most frequently identified from a list were worrying (73.2%), anxiety (66.2%) and anger (53.5%). Knowledge of precipitant factors may have implications on the treatment and seizure control of patients.


Subject(s)
Epilepsy, Temporal Lobe/etiology , Epilepsy, Temporal Lobe/psychology , Interpersonal Relations , Relaxation Therapy/psychology , Seizures/etiology , Seizures/psychology , Adolescent , Adult , Anxiety/psychology , Epilepsy, Temporal Lobe/prevention & control , Female , Follow-Up Studies , Humans , Male , Menstruation/psychology , Middle Aged , Seizures/prevention & control , Surveys and Questionnaires , Young Adult
6.
Exp Neurol ; 181(2): 224-30, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12781995

ABSTRACT

Kindling is a model of temporal lobe epilepsy in which repeated electrical stimulations in limbic areas lead to progressive increase of seizure susceptibility, culminating in generalized convulsions and the establishment of a permanent epileptic syndrome. We studied here the effect of stimulations in the thalamic reticular nucleus (TRN) on the development of seizures and hippocampal hyperexcitability in kindling elicited from the ventral hippocampus in rats. Animals given 12 kindling stimulations per day with 30-min intervals for 4 consecutive days developed generalized convulsions on day 4. Stimulations in TRN delivered simultaneously with those in the hippocampus induced marked suppression of seizure generalization. Similarly, the number of generalized seizures and the duration of behavioral convulsions were reduced when rats subjected to 40 kindling stimulations with 5-min intervals during about 3 h were costimulated in the TRN. The anticonvulsant effect of TRN costimulation was detected also when rats were test-stimulated in the hippocampus at 24 h and 2 and 4 weeks after the initial 40 hippocampal stimulations. Our data provide the first evidence that TRN stimulations can act to suppress limbic motor seizures in hippocampal kindling and suggest a new approach for seizure control in temporal lobe epilepsy.


Subject(s)
Electric Stimulation Therapy/methods , Intralaminar Thalamic Nuclei/physiology , Limbic System/physiopathology , Seizures/physiopathology , Seizures/therapy , Animals , Disease Models, Animal , Epilepsy, Temporal Lobe/physiopathology , Epilepsy, Temporal Lobe/prevention & control , Epilepsy, Temporal Lobe/therapy , Hippocampus/physiopathology , Kindling, Neurologic , Male , Rats , Rats, Wistar , Seizures/prevention & control , Treatment Outcome
7.
J Clin Neurophysiol ; 17(1): 29-42, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10709809

ABSTRACT

Positron emission tomography (PET) is a relatively noninvasive neuroimaging method by means of which a large variety of human brain functions can be assessed. Localized neurochemical abnormalities detected by PET were found in patients with partial epilepsy and suggested the use of this modality for localizing epileptogenic regions of the brain. The clinical usefulness of PET is determined by its sensitivity and specificity for identifying epileptogenic areas as defined by ictal surface and intracranial EEG recordings. The findings obtained from comparative EEG and glucose PET data are reviewed with special emphasis on patients undergoing presurgical evaluation because of medically intractable temporal and extratemporal lobe epilepsy. The utility of glucose PET studies for identifying regions of seizure onset is presented, and the limited specificity of glucose metabolic abnormalities for the detection of various EEG patterns in clinical epilepsy is discussed. The authors review the available intracranial EEG and PET comparisons using [11C]flumazenil (FMZ) PET, a tracer for the assessment of tau-amino-butyric acid/benzodiazepine receptor function. They also summarize their experience with [11C]flumazenil PET in identifying cortical regions that show various ictal and interictal cortical EEG abnormalities in patients with extratemporal seizure origin. Finally, the authors demonstrate that further development of new PET tracers, such as alpha-[11C]methyl-L-tryptophan, is feasible and clinically useful and may increase the number of patients in whom PET studies can replace invasive EEG monitoring.


Subject(s)
Brain Diseases/diagnosis , Electroencephalography/methods , Epilepsy/etiology , Epilepsy/prevention & control , Tomography, Emission-Computed/methods , Biomarkers/analysis , Brain Diseases/complications , Brain Diseases/metabolism , Brain Diseases, Metabolic/complications , Brain Diseases, Metabolic/diagnosis , Epilepsy/metabolism , Epilepsy, Temporal Lobe/etiology , Epilepsy, Temporal Lobe/metabolism , Epilepsy, Temporal Lobe/prevention & control , Flumazenil , Glucose/metabolism , Humans , Receptors, GABA-A/metabolism , Thalamus/diagnostic imaging
8.
Epilepsia ; 41(2): 158-69, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10691112

ABSTRACT

PURPOSE: To investigate the clinical, electroencephalographic (EEG), and histopathologic effects of subacute electrical stimulation of the hippocampal formation or gyrus (SAHCS) on 10 patients with intractable temporal lobe seizures. METHODS: Bilateral, depth, hippocampal or unilateral, subdural, basotemporal electrodes were implanted in all 10 patients for a topographic diagnosis of the site and extent of the epileptic focus before a temporal lobectomy. In all patients, antiepileptic drugs (AEDs) were discontinued from 48 to 72 h before a program of continuous SAHCS, which was performed for 2-3 weeks. Stimulation parameters were biphasic Lilly wave pulses, 130/s in frequency, 450 micros in duration, and 200-400 microA in amplitude. The stimuli were delivered 23 of every 24 h for the 2-3-week SAHCS period. The effects of SAHCS on the number of clinical seizures per day and the percentage of interictal EEG spikes per 10-second samples of maximal paroxysmal activity at the epileptic focus were determined daily during the 16 days of SAHCS. At the completion of this program, patients underwent an en bloc temporal lobectomy, and the histopathologic effects of SAHCS on the stimulated tissue were analyzed by means of light-microscopy studies. RESULTS: In seven patients whose stimulation electrode contacts were placed within the hippocampal formation or gyrus and who experienced no interruption in the stimulation program, SAHCS abolished clinical seizures and significantly decreased the number of interictal EEG spikes at the focus after 5-6 days. The most evident and fast responses were found by stimulating either the anterior pes hippocampus close to the amygdala or the anterior parahippocampal gyrus close to the entorhinal cortex. Other surface, hippocampal, and basotemporal EEG signs predicted and accompanied this antiepileptic response. These included an electropositive DC shift and monomorphic delta activity at the medial hippocampal and parahippocampal regions, and a normalization of the background EEG activity and signs of slow-wave sleep in surface. depth, and subdural regions. In contrast, no evident antiepileptic responses or no responses at all were found in three patients when stimulation was either interrupted or when it was administered outside the hippocampus. Light microscopy analysis of the stimulated hippocampal tissue showed histopathological abnormalities attributable to the depth-electrode penetration damage or to the pial surface reaction to the subdural, Silastic electrode plate. However, no evident histopathological differences were found between the stimulated and nonstimulated hippocampal tissue. CONCLUSIONS: SAHCS appears to be a safe procedure that can suppress temporal lobe epileptogenesis with no additional damage to the stimulated tissue.


Subject(s)
Electric Stimulation Therapy , Electroencephalography/statistics & numerical data , Epilepsy, Temporal Lobe/prevention & control , Hippocampus/physiology , Seizures/prevention & control , Adult , Animals , Dentate Gyrus/pathology , Dentate Gyrus/physiology , Dentate Gyrus/physiopathology , Electrodes, Implanted , Epilepsy, Temporal Lobe/pathology , Epilepsy, Temporal Lobe/physiopathology , Female , Haplorhini , Hippocampus/pathology , Hippocampus/physiopathology , Humans , Male , Seizures/pathology , Seizures/physiopathology
9.
Epilepsia ; 39(2): 140-9, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9577993

ABSTRACT

PURPOSE: The hypothesis tested in this study was that a unilateral irritative focal epileptic lesion in the temporal lobe results in hyposexuality. METHODS: Focal epilepsy was produced in male cats by unilateral injection of aluminum hydroxide into either the basolateral amygdala (temporal lobe group) or anterior sigmoid gyrus (motor cortex group). Weekly sex testing trials with estrous females were conducted prior to and after aluminum hydroxide injection, and mating performance scores were compared with those of normal, unoperated cats (normal control group). RESULTS: All animals receiving aluminum hydroxide developed electroencephalographic and behavioral manifestations of epilepsy; i.e., interictal EEG spiking and partial or generalized seizures. Cats in the temporal lobe group exhibited a dramatic and complete suppression of sexual behavior at periods from 6 to 26 weeks after aluminum hydroxide injection. The duration of the hyposexuality varied between individual animals and returned to normal as suddenly as the onset occurred, despite the use of AEDs to prevent or control generalized seizure activity. Interictal EEG epileptiform spiking in the amygdala preceded the onset of hyposexuality by 1-12 weeks. By contrast, cats in the motor cortex and normal control groups showed no sign of sexual dysfunction throughout the experimental period, independent of seizure activity and/or antiepileptic drug (AED) treatment. CONCLUSIONS: These data support the hypothesis that hyposexuality occurs as a result of epileptiform activity in the temporal lobe, but not in the motor cortex. The precise mechanisms by which this occurs are unknown, but are likely to involve abnormally high-frequency neuronal activity in temporal lobe structures known to connect with and/or to regulate hypothalamic nuclei that organize male sexual behavior toward receptive females.


Subject(s)
Epilepsy, Temporal Lobe/chemically induced , Sexual Behavior, Animal/physiology , Temporal Lobe/physiology , Aluminum Hydroxide/pharmacology , Amygdala/drug effects , Amygdala/physiology , Animals , Anticonvulsants/pharmacology , Cats , Electroencephalography , Epilepsy, Generalized/chemically induced , Epilepsy, Generalized/prevention & control , Epilepsy, Temporal Lobe/prevention & control , Estrus/physiology , Female , Hypothalamus/drug effects , Hypothalamus/physiology , Male , Motor Cortex/drug effects , Motor Cortex/physiology , Sexual Behavior, Animal/drug effects , Temporal Lobe/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL